News

The intra-articular injection method with RegenoGel is highly praised for its safety, proven effectiveness, simple technique, and reasonable cost, making it suitable for a wide range of patients.

What sets RegenoGel apart is the exclusive technology developed by Procore. The product combines high molecular weight natural hyaluronic acid with fibrinogen, a key plasma component involved in wound healing and tissue repair. Thanks to its chemically bonded structure, RegenoGel is free from animal-derived components, offering high biological safety and optimal compatibility with the human body.

RegenoGel effectively reduces pain caused by joint degeneration, helps improve mobility, and maintains treatment results for up to 12 months. It’s an ideal solution for patients seeking a sustainable treatment method with minimal side effects.

Regenogel is effective for patients with osteoarthritis

RegenoGel, an advanced injectable gel for joint treatment, has been officially certified as a medical device by the Medical Devices Division (AMAR) of the Israel Ministry of Health, specifically for patients suffering from knee osteoarthritis.

This certification follows a series of rigorous pre-clinical and clinical trials, conducted in collaboration between Procore and the Orthopedic Department of Assaf Ha’Rofeh Medical Center. The clinical study involved patients with severe osteoarthritis, all of whom were scheduled for total knee replacement surgery.

This achievement marks an important milestone in the long-standing collaboration between Procore and leading orthopedic experts, under the leadership of Prof. Nachum Halperin and Dr. Gavriel Eger.

High Prevalence of Musculoskeletal Conditions Among Adults in Vietnam

Data from the healthcare sector indicates that Vietnam ranks among the countries with a high rate of musculoskeletal disorders. Specifically, approximately 30% of people over the age of 35, 60% of those over 65, and up to 85% of individuals over 85 suffer from joint degeneration-related conditions.

Joint problems not only cause prolonged pain but also seriously affect mobility and quality of life, especially among the elderly.

In response to this reality, the healthcare sector is promoting research and the application of supportive treatment solutions to improve patients’ quality of life.

Musculoskeletal disorders are increasingly affecting younger individuals

Joint Injection Gel – A Popular Conservative Treatment Option

Currently, there is no definitive cure for chronic musculoskeletal conditions, particularly age-related osteoarthritis. Treatment approaches mainly focus on pain relief, maintaining joint function, and slowing disease progression.

Among these, intra-articular injections using gel containing Hyaluronic Acid (HA) are a commonly adopted treatment due to their effectiveness in quickly relieving pain and improving joint function.

RegenoGel – A Joint Injection Gel Developed with Advanced Biotechnology

RegenoGel is a product developed by Procore Bio Med (Israel), a biotechnology company specializing in solutions for patients with musculoskeletal disorders.

The product is based on the proprietary HAProLink technology, which combines Hyaluronic Acid with a specific protein to create a favorable environment for cartilage and bone regeneration. RegenoGel has been approved for circulation by the Israeli Ministry of Health since 2016.

Features and Benefits of RegenoGel

RegenoGel is a viscous gel injected directly into the joint, offering long-lasting pain relief and supporting the repair of cartilage damaged by arthritis or trauma-induced degeneration.

The product is formulated with a proprietary blend aimed at slowing down degeneration and protecting joints from further damage.

RegenoGel helps provide long-lasting joint pain relief

RegenoGel’s Unique Mechanism of Action

RegenoGel works in two phases:

• In the initial phase, it remains in a liquid state, allowing it to easily infiltrate and fill joint lesions.

• Subsequently, it transforms into an insoluble gel, forming a mechanical cushion that reduces pressure, lubricates the joint, and supports joint function.

RegenoGel utilizes high molecular weight HA—a natural component in the body that aids lubrication, elasticity, and inflammation reduction—combined with fibrinogen, a critical protein in tissue regeneration and wound healing.

This combination creates a stable gel system that not only provides mechanical support but also promotes biological healing, helping reduce pain quickly and slow down the progression of joint degeneration.

What Sets RegenoGel Apart from Other Intra-Articular Injections

Unlike products containing only pure HA, RegenoGel employs Procore’s proprietary crosslinking technology to form a stable gel immediately after injection. This allows for longer retention within the joint and more sustained effectiveness.

Additionally, RegenoGel not only alleviates pain but also fosters a biologically supportive environment for joint recovery. Its transformation from liquid to gel post-injection makes the procedure smoother and reduces discomfort for patients.

RegenoGel promotes the production of endogenous hyaluronic acid (HA)

Who Can Use RegenoGel?

RegenoGel is indicated for patients with degenerative joint conditions such as osteoarthritis affecting the knees, hips, shoulders, and ankles.

It is suitable for a wide range of individuals—from athletes with injuries to elderly patients with age-related joint degeneration. The treatment is administered by a specialist and typically requires only one injection, with effects lasting for at least three months.

Note: RegenoGel is a specialized medical product and should only be used under the supervision and prescription of a healthcare professional.

For more information about RegenoGel intra-articular injection gel, please leave your contact details on our website to receive support.

Goodie Vietnam officially holds the circulation registration number under Decree 98 for the Regenogel product in the Vietnamese market. It is the sole company in Vietnam to have this registration to date.

Goodie VN JSC., is the exclusive entity in Vietnam that holds a valid and permanent registration number (also know as import license as Circular 30, will be expired on June 30) for the product Regenogel. This official authorization, granted by the competent regulatory authority, affirms GVN’s legal capacity to import and distribute Regenogel on a continuous basis, in full compliance with applicable laws and regulations. It also reflects GVN’s enduring commitment to providing high-quality, approved healthcare solutions to the Vietnamese market.

Procore extends distribution of Regenogel-OSP to private clinics and medical centers in Israel.

RegenoGel-OSP is an autologous version of RegenoGel with an added layer of personalized properties. RegenoGel-OSP (On Site Plasma) combines high molecular weight hyaluronic acid (HA) with the patient’s own plasma.

ICRS 2022 Berlin World Congress – Abstract Submission.

Procore has submitted an abstract to participate in a large-scale congress of a unique worldwide forum for cartilage regeneration and joint preservation.

Import license; submitted in India. The company filed an application for the registration of RegenoGel in India